X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-03-12 | CYRX | Cryoport, Inc. | Stefanovich Robert | CFO | S - Sale+OE | $7.78 | -41,443 | 280,371 | -13% | -$322,330 | |||||
| D | 2026-03-13 | EQ | Equillium, Inc. | Zedelmayer Christine | SVP, COO | S - Sale+OE | $2.50 | -120,312 | 62,586 | -66% | -$300,816 | |||||
| AD | 2026-03-13 | CNTA | Centessa Pharmaceuticals Plc | Anderson Karen M. | Chief People Officer | S - Sale+OE | $26.25 | -120,029 | 62,085 | -66% | -$3,150,673 | |||||
| M | 2026-03-12 | BBIO | Bridgebio Pharma, Inc. | Kumar Neil | CEO | S - Sale | $68.76 | -80,000 | 5,308,584 | -1% | -$5,501,068 | |||||
| DM | 2026-03-12 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $26.61 | -20,406 | 76,140 | -21% | -$542,973 | |||||
2026-03-16 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale | $61.03 | -1,709 | 46,149 | -4% | -$104,300 | ||||||
2026-03-16 | UTHR | United Therapeutics Corp | Olian Judy D. | Dir | S - Sale | $535.44 | -200 | 4,445 | -4% | -$107,088 | ||||||
| DM | 2026-03-12 | NUVL | Nuvalent, Inc. | Pelish Henry E. | Chief Scientific Officer | S - Sale+OE | $98.08 | -35,104 | 65,604 | -35% | -$3,442,856 | |||||
| D | 2026-03-13 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $538.00 | -9,500 | 639,489 | -1% | -$5,110,967 | |||||
2026-03-16 | ABEO | Abeona Therapeutics Inc. | Vazzano Joseph Walter | CFO | S - Sale | $4.76 | -785 | 567,775 | 0% | -$3,737 | ||||||
| D | 2026-03-13 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale+OE | $48.91 | -5,280 | 113,040 | -4% | -$258,245 | |||||
| D | 2026-03-13 | ZLAB | Zai Lab Ltd | Smiley Joshua L | See Remarks | S - Sale+OE | $18.63 | -1,966 | 91,026 | -2% | -$36,623 | |||||
| D | 2026-03-13 | ZLAB | Zai Lab Ltd | Edmondson Frazor Titus III | GC | S - Sale+OE | $18.63 | -1,281 | 6,494 | -16% | -$23,862 | |||||
| D | 2026-03-13 | ZLAB | Zai Lab Ltd | Chen Yajing | CFO | S - Sale+OE | $18.63 | -1,703 | 19,999 | -8% | -$31,723 | |||||
2026-03-13 | SUPN | Supernus Pharmaceuticals, Inc. | Khattar Jack A. | Pres, CEO | S - Sale | $50.38 | -35,000 | 2,199,244 | -2% | -$1,763,124 | ||||||
| D | 2026-03-13 | ZLAB | Zai Lab Ltd | Amado Rafael | See Remarks | S - Sale+OE | $18.63 | -2,957 | 44,757 | -6% | -$55,083 | |||||
2026-03-12 | SUPN | Supernus Pharmaceuticals, Inc. | Hudson Frederick M. | Dir | S - Sale | $50.61 | -5,369 | 60,413 | -8% | -$271,725 | ||||||
2026-03-13 | NATR | Natures Sunshine Products Inc | Lanoy Jonathan David | SVP, Chief Accounting Officer | S - Sale | $24.70 | -4,000 | 46,405 | -8% | -$98,800 | ||||||
| DM | 2026-03-12 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $537.81 | -9,500 | 639,489 | -1% | -$5,109,148 | |||||
2026-03-13 | MBX | Mbx Biosciences, Inc. | Hawryluk P. Kent | Pres, CEO | P - Purchase | $28.41 | +18,500 | 1,215,051 | +2% | +$525,663 | ||||||
| D | 2026-03-12 | DNTH | Dianthus Therapeutics, Inc. /De/ | Garcia Marino | CEO, Pres | S - Sale+OE | $81.49 | -122,918 | 0 | -100% | -$10,016,381 | |||||
| D | 2026-03-12 | DNTH | Dianthus Therapeutics, Inc. /De/ | Carr Edward | CHIEF ACCOUNTING OFFICER | S - Sale+OE | $81.49 | -43,682 | 0 | -100% | -$3,559,495 | |||||
| D | 2026-03-12 | DNTH | Dianthus Therapeutics, Inc. /De/ | Randhawa Simrat | EVP, Head of R, D | S - Sale+OE | $81.48 | -33,830 | 0 | -100% | -$2,756,468 | |||||
| D | 2026-03-13 | XENE | Xenon Pharmaceuticals Inc. | Kenney Christopher John | Chief Medical Officer | S - Sale+OE | $55.23 | -1,410 | 7,069 | -17% | -$77,867 | |||||
| D | 2026-03-13 | XENE | Xenon Pharmaceuticals Inc. | Difabio Andrea | GC | S - Sale+OE | $55.23 | -1,342 | 7,301 | -16% | -$74,112 | |||||
| D | 2026-03-13 | XENE | Xenon Pharmaceuticals Inc. | Mortimer Ian | Pres, CEO | S - Sale+OE | $55.23 | -7,308 | 34,223 | -18% | -$403,584 | |||||
2026-03-12 | SRPT | Sarepta Therapeutics, Inc. | Mayo Stephen | Dir | S - Sale | $17.02 | -7,239 | 1,765 | -80% | -$123,208 | ||||||
| D | 2026-03-11 | LGND | Ligand Pharmaceuticals Inc | Espinoza Octavio | CFO | S - Sale+OE | $225.00 | -3,057 | 21,010 | -13% | -$687,825 | |||||
| D | 2026-03-13 | CNTA | Centessa Pharmaceuticals Plc | Anderson Karen M. | Chief People Officer | S - Sale+OE | $26.25 | -120,029 | 62,085 | -66% | -$3,150,673 | |||||
2026-03-13 | CNTA | Centessa Pharmaceuticals Plc | Weinhoff Gregory M | Chief Business Officer | S - Sale | $26.33 | -73,196 | 65,925 | -53% | -$1,927,131 | ||||||
2026-03-12 | CRNX | Crinetics Pharmaceuticals, Inc. | Vivaldi Coelho Rogerio | Dir | S - Sale | $36.15 | -5,000 | 16,300 | -23% | -$180,761 | ||||||
2026-03-11 | ANIP | Ani Pharmaceuticals Inc | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | S - Sale | $74.91 | -4,772 | 38,730 | -11% | -$357,471 | ||||||
2026-03-13 | ANIP | Ani Pharmaceuticals Inc | Mutz Christopher | HEAD OF RARE DISEASE | S - Sale | $71.64 | -3,162 | 91,309 | -3% | -$226,526 | ||||||
2026-03-13 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $72.62 | -500 | 79,390 | -1% | -$36,310 | ||||||
| D | 2026-03-11 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale+OE | $300.00 | -341 | 318,370 | 0% | -$102,300 | |||||
2026-03-12 | PTCT | Ptc Therapeutics, Inc. | Klein Matthew B. | CEO | S - Sale | $64.08 | -2,662 | 396,920 | -1% | -$170,581 | ||||||
2026-03-11 | DYN | Dyne Therapeutics, Inc. | Posner Brian S | Dir | P - Purchase | $19.35 | +2,000 | 13,500 | +17% | +$38,700 | ||||||
2026-03-11 | DYN | Dyne Therapeutics, Inc. | Kersten Dirk | Dir | S - Sale | $19.52 | -129,672 | 4,644,386 | -3% | -$2,530,562 | ||||||
2026-03-13 | INDV | Indivior Pharmaceuticals, Inc. | Ryan Barbara | Dir | P - Purchase | $31.09 | +8 | 5,724 | 0% | +$249 | ||||||
2026-03-11 | VRTX | Vertex Pharmaceuticals Inc / Ma | McKechnie Duncan | EVP, Chief Commercial Officer | S - Sale | $498.42 | -2,633 | 12,489 | -17% | -$1,312,340 | ||||||
2026-03-11 | ONCY | Oncolytics Biotech Inc | Parsons James T. | Dir | P - Purchase | $1.03 | +10,000 | 41,849 | +31% | +$10,300 | ||||||
2026-03-12 | ONCY | Oncolytics Biotech Inc | Kelly Jared | CEO | P - Purchase | $0.96 | +5,050 | 114,050 | +5% | +$4,848 | ||||||
| D | 2026-03-10 | KRRO | Korro Bio, Inc. | Yang Rick | 10% | P - Purchase | $11.11 | +207,100 | 1,297,893 | +19% | +$2,300,881 | |||||
| D | 2026-03-10 | KRRO | Korro Bio, Inc. | Sandell Scott D | 10% | P - Purchase | $11.11 | +207,100 | 1,297,893 | +19% | +$2,300,881 | |||||
| D | 2026-03-10 | KRRO | Korro Bio, Inc. | New Enterprise Associates 17, L.P. | 10% | P - Purchase | $11.11 | +207,100 | 1,297,893 | +19% | +$2,300,881 | |||||
| D | 2026-03-10 | KRRO | Korro Bio, Inc. | Chang Carmen | 10% | P - Purchase | $11.11 | +207,100 | 1,297,893 | +19% | +$2,300,881 | |||||
| D | 2026-03-10 | KRRO | Korro Bio, Inc. | Baskett Forest | 10% | P - Purchase | $11.11 | +207,100 | 1,297,893 | +19% | +$2,300,881 | |||||
| D | 2026-03-10 | KRRO | Korro Bio, Inc. | Mathers Edward T | 10% | P - Purchase | $11.11 | +207,100 | 1,297,893 | +19% | +$2,300,881 | |||||
| D | 2026-03-10 | KRRO | Korro Bio, Inc. | Makhzoumi Mohamad | 10% | P - Purchase | $11.11 | +207,100 | 1,297,893 | +19% | +$2,300,881 | |||||
| D | 2026-03-10 | KRRO | Korro Bio, Inc. | Walker Paul Edward | 10% | P - Purchase | $11.11 | +207,100 | 1,297,893 | +19% | +$2,300,881 | |||||
| D | 2026-03-10 | KRRO | Korro Bio, Inc. | Florence Anthony A. Jr. | 10% | P - Purchase | $11.11 | +207,100 | 1,297,893 | +19% | +$2,300,881 | |||||
2026-03-11 | BMRN | Biomarin Pharmaceutical Inc | Guyer Charles Greg | EVP, Chief Technical Officer | S - Sale | $60.46 | -16,486 | 79,953 | -17% | -$996,744 | ||||||
| D | 2026-03-10 | PTCT | Ptc Therapeutics, Inc. | Okey Stephanie | Dir | S - Sale+OE | $70.00 | -15,167 | 8,000 | -65% | -$1,061,690 | |||||
| D | 2026-03-10 | STOK | Stoke Therapeutics, Inc. | Tzianabos Arthur | Interim Exec Chair | S - Sale+OE | $40.00 | -4,355 | 31,339 | -12% | -$174,214 | |||||
2026-03-10 | STOK | Stoke Therapeutics, Inc. | Krainer Adrian R. | Dir | S - Sale | $39.74 | -33,243 | 283,302 | -11% | -$1,320,964 | ||||||
2026-03-10 | ANNX | Annexon, Inc. | Carson William H. | Dir | P - Purchase | $5.67 | +8,000 | 62,405 | +15% | +$45,360 | ||||||
2026-03-11 | NAMS | Newamsterdam Pharma Co N.V. | Lange Louis G | Dir | S - Sale | $30.42 | -44,619 | 10,360 | -81% | -$1,357,230 | ||||||
| D | 2026-03-10 | BBIO | Bridgebio Pharma, Inc. | Valantine Hannah | Dir | S - Sale+OE | $72.00 | -8,671 | 7,863 | -52% | -$624,312 | |||||
| D | 2026-03-11 | ZLAB | Zai Lab Ltd | Du Ying | Chairperson, CEO | S - Sale+OE | $19.08 | -1,067 | 1,109,905 | 0% | -$20,363 | |||||
| M | 2026-03-10 | IMNM | Immunome Inc. | Bienaime Jean Jacques | Dir | P - Purchase | $21.84 | +2,000 | 38,415 | +5% | +$43,670 | |||||
2026-03-09 | ORGO | Organogenesis Holdings Inc. | Leibowitz Arthur S | Dir | P - Purchase | $2.68 | +5,000 | 291,014 | +2% | +$13,405 | ||||||
| A | 2026-02-19 | EQ | Equillium, Inc. | Zedelmayer Christine | SVP, COO | S - Sale | $1.76 | -185,937 | 91,444 | -67% | -$328,104 | |||||
| D | 2026-03-09 | EQ | Equillium, Inc. | Zedelmayer Christine | SVP, COO | S - Sale+OE | $2.00 | -181,219 | 62,586 | -74% | -$362,438 | |||||
| D | 2026-03-11 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $539.54 | -9,500 | 639,489 | -1% | -$5,125,647 | |||||
| D | 2026-03-10 | XENE | Xenon Pharmaceuticals Inc. | Kenney Christopher John | Chief Medical Officer | S - Sale+OE | $60.11 | -2,771 | 4,729 | -37% | -$166,559 | |||||
| D | 2026-03-10 | XENE | Xenon Pharmaceuticals Inc. | Difabio Andrea | GC | S - Sale+OE | $60.11 | -2,607 | 4,893 | -35% | -$156,702 | |||||
| DM | 2026-03-09 | XENE | Xenon Pharmaceuticals Inc. | Mortimer Ian | Pres, CEO | S - Sale+OE | $60.32 | -281,269 | 29,031 | -91% | -$16,966,500 | |||||
2026-03-09 | ORGO | Organogenesis Holdings Inc. | Driscoll Michael Joseph | Dir | P - Purchase | $2.67 | +10,000 | 225,707 | +5% | +$26,688 | ||||||
| M | 2026-03-09 | DYN | Dyne Therapeutics, Inc. | Kersten Dirk | Dir | S - Sale | $19.09 | -688,788 | 4,774,058 | -13% | -$13,149,314 | |||||
2026-02-26 | EDSA | Edesa Biotech, Inc. | Brooks Michael J | Pres | P - Purchase | $1.57 | +2,000 | 226,870 | +1% | +$3,140 | ||||||
| D | 2026-03-09 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | CEO | S - Sale+OE | $19.17 | -36,766 | 339,392 | -10% | -$704,657 | |||||
| M | 2026-03-09 | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | Pres, COO | S - Sale | $13.04 | -15,010 | 198,588 | -7% | -$195,771 | |||||
| M | 2026-03-09 | TRDA | Entrada Therapeutics, Inc. | Wentworth Kory James | CFO | S - Sale | $13.01 | -16,477 | 121,510 | -12% | -$214,379 | |||||
2026-03-09 | KROS | Keros Therapeutics, Inc. | Bienaime Jean Jacques | Dir | P - Purchase | $11.21 | +2,000 | 7,450 | +37% | +$22,420 | ||||||
| D | 2026-03-10 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $539.71 | -9,500 | 639,489 | -1% | -$5,127,273 | |||||
| D | 2026-03-09 | LQDA | Liquidia Corp | Moomaw Scott | Chief Commercial Officer | S - Sale+OE | $35.32 | -80,000 | 188,954 | -30% | -$2,825,824 | |||||
2026-03-09 | IONS | Ionis Pharmaceuticals Inc | O'Neil Patrick R. | EVP CLO, GC | S - Sale | $75.25 | -10,148 | 62,211 | -14% | -$763,662 | ||||||
2026-03-09 | COLL | Collegium Pharmaceutical, Inc | Dieter David | EVP, GC | S - Sale | $36.65 | -6,224 | 91,047 | -6% | -$228,110 | ||||||
| D | 2026-03-10 | AQST | Aquestive Therapeutics, Inc. | Boyd Peter E. | Chief People Officer | S - Sale+OE | $4.17 | -29,814 | 338,509 | -8% | -$124,414 | |||||
| D | 2026-03-10 | AQST | Aquestive Therapeutics, Inc. | Barber Daniel | Pres, CEO | S - Sale+OE | $4.17 | -180,677 | 1,004,753 | -15% | -$753,965 | |||||
| D | 2026-03-10 | AQST | Aquestive Therapeutics, Inc. | Braender Lori J | GC | S - Sale+OE | $4.17 | -40,102 | 442,879 | -8% | -$167,346 | |||||
| D | 2026-03-10 | AQST | Aquestive Therapeutics, Inc. | Cioffi Melina | SVP, Regulatory Affairs | S - Sale+OE | $4.17 | -25,311 | 274,867 | -8% | -$105,623 | |||||
| D | 2026-03-10 | AQST | Aquestive Therapeutics, Inc. | Toth A Ernest Jr | CFO | S - Sale+OE | $4.17 | -58,254 | 376,112 | -13% | -$243,094 | |||||
| D | 2026-03-10 | AQST | Aquestive Therapeutics, Inc. | Korczynski Sherry | Chief Commercial Officer | S - Sale+OE | $4.17 | -15,741 | 241,117 | -6% | -$65,687 | |||||
| D | 2026-03-10 | AQST | Aquestive Therapeutics, Inc. | Jung Cassie | COO | S - Sale+OE | $4.17 | -45,791 | 276,980 | -14% | -$191,086 | |||||
2026-03-06 | INDV | Indivior Pharmaceuticals, Inc. | Kingsley Stuart A | Dir | P - Purchase | $31.87 | +940 | 5,582 | +20% | +$29,953 | ||||||
2026-03-09 | INDV | Indivior Pharmaceuticals, Inc. | Ryan Barbara | Dir | P - Purchase | $32.56 | +31 | 5,716 | +1% | +$1,009 | ||||||
2026-03-10 | MNKD | Mannkind Corp | Castagna Michael | CEO | P - Purchase | $2.59 | +100,000 | 2,577,411 | +4% | +$259,000 | ||||||
| D | 2026-03-06 | NAMS | Newamsterdam Pharma Co N.V. | Lange Louis G | Dir | S - Sale+OE | $29.41 | -28,186 | 54,979 | -34% | -$828,950 | |||||
| D | 2026-03-02 | WHWK | Whitehawk Therapeutics, Inc. | Lennon David James | CEO | S - Sale+OE | $3.31 | -5,100 | 44,579 | -10% | -$16,879 | |||||
| D | 2026-03-02 | WHWK | Whitehawk Therapeutics, Inc. | Giacobello Scott M. | CFO | S - Sale+OE | $3.31 | -2,594 | 28,100 | -8% | -$8,585 | |||||
| D | 2026-03-02 | WHWK | Whitehawk Therapeutics, Inc. | Ball Bryan | See remarks | S - Sale+OE | $3.31 | -1,834 | 206,019 | -1% | -$6,070 | |||||
| DM | 2025-08-27 | VTRS | Viatris Inc | Simmons David S | Dir | P - Purchase | $10.42 | +499 | 24,527 | +2% | +$5,202 | |||||
| D | 2026-03-09 | KALV | Kalvista Pharmaceuticals, Inc. | Palleiko Benjamin L | CEO | S - Sale+OE | $16.08 | -6,693 | 451,815 | -1% | -$107,633 | |||||
2026-03-10 | VKTX | Viking Therapeutics, Inc. | Aubuchon Neil William | Chief Commercial Officer | P - Purchase | $33.50 | +4,475 | 4,475 | New | +$149,913 | ||||||
2026-03-06 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale | $29.58 | -10,000 | 51,000 | -16% | -$295,839 | ||||||
2026-03-09 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale | $60.72 | -2,582 | 47,858 | -5% | -$156,779 | ||||||
| D | 2026-03-09 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $26.84 | -2,171 | 82,489 | -3% | -$58,270 | |||||
2026-03-06 | DYN | Dyne Therapeutics, Inc. | Posner Brian S | Dir | P - Purchase | $15.06 | +3,000 | 11,500 | +35% | +$45,180 | ||||||
2026-03-10 | EDSA | Edesa Biotech, Inc. | Nijhawan Pardeep | CEO, 10% | P - Purchase | $6.60 | +1,000 | 1,149,241 | 0% | +$6,599 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |